STOCK TITAN
  1. Home
  2. Sec-filings
  3. ARMP
  4. [8-K] Armata Pharmaceuticals, Inc. Reports Material Event

Armata Pharmaceuticals (ARMP) schedules 2026 annual meeting and proposal deadline

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Armata Pharmaceuticals, Inc. has scheduled its 2026 annual meeting of stockholders for June 11, 2026 at 8:30 a.m. Pacific Time at its principal executive offices in Los Angeles, California. Stockholders of record at the close of business on April 17, 2026 will be entitled to receive notice and vote at the meeting.

The company has set 5:00 p.m. Pacific Time on April 12, 2026 as the deadline for receipt of stockholder proposals and director nominations submitted under Section 2.6 of its Amended and Restated Bylaws. Proposals and nominations must be delivered in writing to the Corporate Secretary at Armata’s principal executive offices and must comply with the advance notice provisions in the bylaws.

Positive

  • None.

Negative

  • None.
Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Annual meeting date June 11, 2026 Date of 2026 annual meeting of stockholders at 8:30 a.m. Pacific Time
Record date April 17, 2026 Stockholders of record at close of business may vote at the meeting
Proposal deadline April 12, 2026, 5:00 p.m. PT Deadline for receipt of stockholder proposals and director nominations
Meeting time 8:30 a.m. Pacific Time Scheduled start time for the 2026 annual meeting
Meeting location 5005 McConnell Avenue, Los Angeles, CA 90066 Principal executive offices where the meeting is scheduled
annual meeting of stockholders financial
"Armata Pharmaceuticals, Inc. has set June 11, 2026 as the date for its 2026 annual meeting of stockholders"
stockholders of record financial
"Armata’s stockholders of record at the close of business on April 17, 2026, will be entitled to notice"
Stockholders of record are the people or entities whose names appear on a company's official shareholder list on a specific cutoff date set by the company or its transfer agent; only those listed are entitled to receive dividends, vote at shareholder meetings, or participate in other corporate actions. Think of it like a guest list for an event: being on the list on the set day determines who gets the benefits and rights, so investors must own shares before the cutoff to qualify.
advance notice bylaw provisions regulatory
"Stockholder proposals and nominations submitted pursuant to Armata’s advance notice bylaw provisions must also comply"
Amended and Restated Bylaws regulatory
"Section 2.6 of Armata’s Amended and Restated Bylaws for consideration at the Annual Meeting"
A company’s amended and restated bylaws are its internal rulebook rewritten to include all changes in one updated document, replacing the old bylaws. For investors, this matters because the bylaws set how the board, shareholders and officers make decisions, hold votes and handle disputes; a new consolidated version can change voting rights, control mechanisms or procedures that affect corporate governance and the value or risk of an investment.
proxy statement financial
"set forth in the Company’s proxy statement for the Annual Meeting"
A proxy statement is a document companies send to shareholders ahead of a meeting that lays out the items up for a vote—like who will sit on the board, executive pay, and major corporate decisions—and provides background so shareholders can decide how to cast their votes or appoint someone to vote for them. Think of it as an agenda plus a ballot and briefing notes, important because the outcomes can change control, strategy, and value.
Understanding 8-K Material Events →
false 0000921114 0000921114 2026-04-02 2026-04-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): April 2, 2026

 

ARMATA PHARMACEUTICALS, INC.

(Exact name of Registrant as specified in its charter)

 

Washington   001-37544   91-1549568
(State or other jurisdiction
of incorporation or organization)		   (Commission File Number)   (IRS Employer Identification No.)

 

  5005 McConnell Avenue
Los Angeles, California		   90066
  (Address of principal executive offices)   (Zip Code)

 

(310) 655-2928

(Registrant’s Telephone number)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class   Trading Symbol(s)   Name of Each Exchange on Which Registered
Common Stock   ARMP   NYSE American

 

 

 

 

 

 

Item 8.01 Other Events.

 

Armata Pharmaceuticals, Inc. (“Armata” or the “Company”) has set June 11, 2026 as the date for its 2026 annual meeting of stockholders (the “Annual Meeting”). The Annual Meeting will be held at 8:30 a.m. (Pacific Time), at the Company’s principal executive offices at 5005 McConnell Avenue, Los Angeles, California 90066, or at such other time and location to be determined by the Company’s Board of Directors and set forth in the Company’s proxy statement for the Annual Meeting. Armata’s stockholders of record at the close of business on April 17, 2026, will be entitled to notice of the Annual Meeting and to vote upon matters considered at the Annual Meeting.

 

The deadline for receipt of stockholder proposals and director nominations submitted pursuant to Section 2.6 of Armata’s Amended and Restated Bylaws for consideration at the Annual Meeting is 5:00 p.m. (Pacific Time) on April 12, 2026 (the “Advance Notice Bylaws Provision Deadline”). Stockholder proposals and director nominations should be submitted in writing and must be received by the Corporate Secretary at Armata’s principal executive offices at Armata Pharmaceuticals, Inc., 5005 McConnell Avenue, Los Angeles, California 90066, by the Advance Notice Bylaws Provision Deadline, in order to be considered timely. Stockholder proposals and nominations submitted pursuant to Armata’s advance notice bylaw provisions must also comply with the advance notice provisions contained in Armata’s Amended and Restated Bylaws and may be omitted if not in compliance with applicable requirements. Stockholders are urged to read the complete text of such advance notice provisions.

 

-2-

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: April 2, 2026 Armata Pharmaceuticals, Inc.
   
  By: /s/ David House
  Name: David House
  Title: Senior Vice President, Finance and Principal Financial Officer

 

-3-

 

Source: View Original Filing on SEC EDGAR

FAQ

When is Armata Pharmaceuticals (ARMP) holding its 2026 annual meeting?

Armata Pharmaceuticals will hold its 2026 annual meeting of stockholders on June 11, 2026 at 8:30 a.m. Pacific Time. The meeting is scheduled to take place at the company’s principal executive offices in Los Angeles, California, as further detailed in its upcoming proxy statement.

Who is entitled to vote at Armata Pharmaceuticals (ARMP) 2026 annual meeting?

Stockholders of Armata Pharmaceuticals of record at the close of business on April 17, 2026 are entitled to vote at the 2026 annual meeting. This record date determines which stockholders may receive notice of the meeting and vote on matters presented.

What is the deadline to submit stockholder proposals for Armata Pharmaceuticals (ARMP) 2026 meeting?

The deadline for stockholder proposals and director nominations under Armata’s advance notice bylaw provisions is 5:00 p.m. Pacific Time on April 12, 2026. Submissions must be received in writing by the Corporate Secretary at the company’s principal executive offices.

Where will Armata Pharmaceuticals (ARMP) 2026 annual meeting be held?

Armata’s 2026 annual meeting is scheduled at its principal executive offices at 5005 McConnell Avenue, Los Angeles, California 90066. The company notes the meeting could be held at another time or location if its board determines and discloses this in the proxy statement.

What requirements apply to Armata Pharmaceuticals (ARMP) stockholder proposals and nominations?

Stockholder proposals and director nominations must comply with Section 2.6 of Armata’s Amended and Restated Bylaws. They must meet the advance notice provisions, be submitted in writing to the Corporate Secretary by the stated deadline, and may be omitted if they do not satisfy applicable requirements.

Filing Exhibits & Attachments

3 documents

Other Documents